A Study Evaluating Efficacy and Safety of CRO-SBT in the Treatment of Gonorrhea

Gonorrhea Clinical Trial

— CRO-SBT  

Official title:

A Study Evaluating Efficacy and Safety of Ceftriaxone Sodium and Sulbactam Sodium for Injection in the Treatment of Uncomplicated Urogenital Gonorrhea

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04202068
• Other study ID #: GC0048-015
• Status: Completed
• Phase: Phase 4
• Start date: July 3, 2015
• Est. completion date: May 30, 2016

Study information

• Verified date: December 2019
• Source: Xiangbei Welman Pharmaceutical Co., Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phaseIV, multicenter, open-label，single arm study which will be performed to evaluate efficacy and safety of Ceftriaxone sodium and Sulbactam Sodium for injection for the treatment of uncomplicated urogenital infection caused by Neisseria gonorrhoeae in adolescent and adult subjects.

Description:

In this study, adults will be administered as one 3g IV dose at the study site,Children under 12 will be administered as one 75mg/kg IV dose . Approximately 100 subjects will be recruited to receive study treatment. The duration of the study will be approximately 14 days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 113
• Est. completion date: May 30, 2016
• Est. primary completion date: May 3, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subjects must be >=6 or ?80 years of age at the time of signing the informed consent,both gender

• Subjects having clinical suspicion of a urogenital gonococcal infection with or without gonococcal infection according to the laboratory test results of symptoms, physical symptoms, gonococcus smear, culture, etc.

• Subjects having clinical suspicion of a gonococcal infection must have both of the following risk factors:once used three generations of cephalosporin invalid, and sensitive to this product (including gonorrhea urethritis, cervicitis, proctitis, pharyngitis).

• Male and female subject must agree to use contraception (male condoms) during intercourse from the Baseline Visit through completion of the TOC Visit.

Exclusion Criteria:

• Subject has a history of sensitivity to the study treatments, or components thereof, or a history of a drug (including erythromycin and any macrolide or ketolide drug) or other allergy that, in the opinion of the investigator or medical monitor, contraindicates his or her participation

• Subject has received any cephalosporinl therapy for the treatment of a gonococcal infection

• Pregnant or lactating women, or women Subject of childbearing age who were unwilling or unable to use acceptable methods of contraception throughout the study period.

• Famale subject who were positive for pregnancy tests at the time of inclusion or before the start of study drug use.

• Subject has risk of potentially serious drug interactions

• Subject has major diseases such as cardiovascular disease, hepatorenal disease and mental disease, or other factors, the researcher should not participate in the study according to comprehensive judgment

• Subject has a known history of alcohol or drug abuse

• Subject has a known any complicated or systemic gonorrhea infection, such as pelvic inflammatory disease, arthritis, endocarditis

Related Conditions & MeSH terms

• Gonorrhea

Intervention

Drug:
• Ceftriaxone sodium and Sulbactam Sodium for injection
Ceftriaxone sodium and Sulbactam Sodium for injection is available as sterile powder for reconstitution.It will be administered as one 3g IV dose for adult or one 75mg/kg IV dose for children under 12.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Xiangbei Welman Pharmaceutical Co., Ltd

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	bacterial eradicatio	Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site at the Test-of-Cure (TOC)	Up to Day 8
Secondary	clinical cure	Number of subjects with disappearance of clinical symptoms and signs at the Test-of-Cure (TOC)	Up to Day 8
Secondary	Comprehensive curative effect	Number of subjects with culture-confirmed bacterial eradication of Neisseria gonorrhoeae from the urogenital site and disappearance of clinical symptoms and signs	Up to Day 8

External Links

•   Link